Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry

J Thorac Oncol. 2013 Dec;8(12):e109-11. doi: 10.1097/01.JTO.0000437502.82078.9b.

Authors

Yan Feng¹, Arun D Singh, Christopher Lanigan, Raymond R Tubbs, Patrick C Ma

Affiliation

¹ Departments of *Translational Hematology and Oncology Research, and†Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; ‡Department of Ophthalmic Oncology, Cole Eye Institute, and §Department of Molecular Pathology, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.

PMID: 24389446
DOI: 10.1097/01.JTO.0000437502.82078.9b

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Anaplastic Lymphoma Kinase
Choroid Neoplasms / drug therapy*
Choroid Neoplasms / genetics
Choroid Neoplasms / secondary
Chromosomes, Human, Pair 2 / genetics*
Crizotinib
DNA, Neoplasm / genetics
Female
Gene Fusion*
Gene Rearrangement
Humans
Immunoenzyme Techniques
In Situ Hybridization, Fluorescence
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Middle Aged
Prognosis
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Receptor Protein-Tyrosine Kinases / genetics*
Receptor Protein-Tyrosine Kinases / metabolism*
Translocation, Genetic / genetics

Substances

DNA, Neoplasm
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases